New Clinical Insights and Data Presented at 29th ECTRIMS Congress Further Advance Teva’s Leadership in Multiple …

JERUSALEM--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (TEVA) today announced that key data from the Companys multiple sclerosis (MS) franchise will be featured in over 20 presentations at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5, 2013. Data presentations will provide new clinical insights on the effects of treatment with COPAXONE (glatiramer acetate injection), the worlds leading relapsing-remitting multiple sclerosis (RRMS) treatment, and the novel effects of laquinimod, Tevas investigational oral compound, when used to treat RRMS.

"With our sixteen year legacy in providing a safe and effective treatment for RRMS, Teva continues to discover and develop treatments that positively impact patients living with this complex, debilitating disease, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical Industries Ltd. The continued investigation of the long-term open-label study of COPAXONE and investigation of laquinimods effect in MS demonstrate our ongoing focus on increasing the body of scientific knowledge available to neurologists for making appropriate treatment decisions in a rapidly evolving landscape.

In addition to presenting data at the Congress, Teva will host two satellite symposia, Emerging Insights in Multiple Sclerosis: Re-evaluating the Treatment Algorithm on Thursday, October 3, 2013 from 13:00 - 14:00 CET and Multiple Sclerosis Management: Have We Got the Focus Right? on Friday, October 4, 2013 from 19:15 - 20:15 CET. Also during the Congress, Teva will host a roundtable event for credentialed journalists focused on the future of the MS treatment landscape and patient journey.

Data Highlights from the Teva MS Franchise

Key data being presented during ECTRIMS from Tevas MS franchise will include twenty-year long-term clinical results from the US open-label extension study of COPAXONE in RRMS, analyses of pooled data from the Phase 3 BRAVO and ALLEGRO clinical trials of laquinimod and results from the open-label extension phase of the BRAVO study.

COPAXONE (glatiramer acetate injection):

Laquinimod:

ABOUT COPAXONE

COPAXONE(glatiramer acetate injection) is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. The most common side effects of COPAXONEare redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. See additional important information at http://copaxone.com/pdfs/PrescribingInformation.aspx. For hardcopy releases, please see enclosed full prescribing information. COPAXONEis now approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.

See the article here:
New Clinical Insights and Data Presented at 29th ECTRIMS Congress Further Advance Teva’s Leadership in Multiple ...